Literature DB >> 2788555

Incidence of Coxsackie virus infection in patients with dilated cardiomyopathy.

I Riecanský1, Z Schreinerová, A Egnerová, A Petrovicová, O Bzduchová.   

Abstract

A total of 127 patients, divided into two groups, were examined; one was made up by patients with dilated cardiomyopathy (D-CMP) (n: 32), the other one by patients with myocarditis and pericarditis ("other cardiopathies") (n: 95). A control group of healthy subjects (n: 278) consisted of blood donors. Infection with Coxsackie viruses (B1, B2, B3, B4, B5, B6, A7, A9) was followed up serologically using virus-neutralizing antibodies and/or IgM class virus-specific antibodies. Actual Coxsackie virus infection was demonstrated in almost half of patients. Seventeen (53.1%) out of the 32 D-CMP patients (with a negative history of Coxsackie virus infection) had a positive serological finding. The most frequently isolated Coxsackie virus was, B4. In the group of "other cardiopathies", a positive serological finding was in 42 patients (44.2%) with the incidence of B1 and B4 viruses being the highest and identical. Compared with data obtained in healthy controls, the incidence of Coxsackie virus infection in the two follow-up groups of patients was statistically highly significant (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788555

Source DB:  PubMed          Journal:  Cor Vasa        ISSN: 0010-8650


  7 in total

1.  Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients.

Authors:  John P Breinholt; Mousumi Moulik; William J Dreyer; Susan W Denfield; Jeffrey J Kim; John L Jefferies; Joseph W Rossano; Corey M Gates; Sarah K Clunie; Karla R Bowles; Debra L Kearney; Neil E Bowles; Jeffrey A Towbin
Journal:  J Heart Lung Transplant       Date:  2010-04-24       Impact factor: 10.247

Review 2.  Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

Authors:  Robert S Fujinami; Matthias G von Herrath; Urs Christen; J Lindsay Whitton
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Immunological and pathological consequences of coxsackievirus RNA persistence in the heart.

Authors:  Claudia T Flynn; Taishi Kimura; Kwesi Frimpong-Boateng; Stephanie Harkins; J Lindsay Whitton
Journal:  Virology       Date:  2017-12       Impact factor: 3.616

4.  Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.

Authors:  M K Slifka; R Pagarigan; I Mena; R Feuer; J L Whitton
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro.

Authors:  Ralph Feuer; Ignacio Mena; Robb Pagarigan; Mark K Slifka; J Lindsay Whitton
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  In vivo ablation of type I interferon receptor from cardiomyocytes delays coxsackieviral clearance and accelerates myocardial disease.

Authors:  Nadine Althof; Stephanie Harkins; Christopher C Kemball; Claudia T Flynn; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

Review 7.  High pressure processing and its application to the challenge of virus-contaminated foods.

Authors:  David H Kingsley
Journal:  Food Environ Virol       Date:  2012-11-20       Impact factor: 2.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.